Table 1.
Patient characteristics
| SLE | RA | |||
|---|---|---|---|---|
| Patients included | 128 | (45.4) | 154 | (54.6) |
| Female sex | 113 | (88.3) | 110 | (71.4) |
| Age, years | 53.8 | (41.4–62.8) | 63.4 | (56.0–71.2) |
| Body mass index, kg/m2 | 24.8 | (21.8–28.4) | 26.3 | (23.0–29.4) |
| Disease duration, years | 14.5 | (7.0–27.0) | 15.5 | (7.0–22.0) |
| Charlson comorbidity score | 2 | (1–3) | 3 | (2–4) |
| Active/previous/never smoker, % | 8.7/35.4/55.9 | 12.1/53.0/34.9 | ||
| Rheumatoid arthritis (RA) | ||||
| Anti-CCP positivity | – | – | 117/153 | (76.5) |
| IgM-RF positivity | – | – | 107 | (69.5) |
| Erosive disease on X-ray | – | – | 122 | (79.2) |
| Systemic Lupus Erythematosus (SLE) | ||||
| ACR classification criteria | ||||
| Malar rash | 81 | (63.3) | – | – |
| Discoid rash | 9 | (7.0) | – | – |
| Photosensitivity | 59 | (46.1) | – | |
| Oral ulcers | 34 | (26.6) | – | – |
| Nonerosive arthritis | 111 | (86.7) | – | – |
| Pleuritis or pericarditis | 37 | (28.9) | – | – |
| Renal disorder | 37 | (28.9) | – | – |
| Neurologic disorder | 10 | (7.8) | – | – |
| Hematologic disorder | 101 | (78.9) | – | – |
| Immunologic disorder | 120 | (93.8) | – | – |
| Positive antinuclear antibody | 126 | (98.4) | – | – |
| SLICC score, median (IQR) | 1 | (0–2) | – | – |
| Treatment | ||||
| Methotrexate | 12 | (9.4) | 82 | (53.2) |
| Salazopyrine | – | – | 8 | (5.2) |
| Hydroxychloroquine | 88 | (68.8) | 2 | (1.3) |
| Prednisone | 49 | (38.3) | 10 | (6.5) |
| Leflunomide | – | – | 14 | (9.1) |
| Azathioprine | 27 | (21.1) | 2 | (1.3) |
| Number of biologics tried, median | – | – | 2 | (1–3) |
| TNF-α-inhibitors | – | – | 79 | (52.7) |
| Rituximab | 5 | (3.9) | 22 | (14.7) |
| JAK-inhibitor | – | – | 16 | (10.7) |
| Anti-IL-6 | – | – | 23 | (15.3) |
| Abatacept | – | – | 10 | (6.7) |
| Mycophenolatemofetil | 22 | (17.2) | – | – |
| Belimumab | 5 | (3.9) | – | – |
| Other (privigen, tacrolimus, ixekizumab) | 5 | (3.9) | 2 | (1.3) |
| No treatment | 17 | (13.3) | 2 | (1.3) |
Table 1 shows patient characteristics of the participants. Values are given as median (IQR) or n (%)
SLE Systemic lupus erythematosus, RA Rheumatoid Arthritis, Anti-CCP Anti-cyclic citrullinated peptide, RF Rheumatoid factor, ACR American College of Rheumatology, SLICC Systemic Lupus International Collaborating Clinics, TNF Tumor Necrosis Factor, JAK Janus kinase, IL Interleukin